Insights

Innovative Microbiome Platform Evelo Biosciences leverages a unique oral delivery platform targeting the small intestinal axis, SINTAX, which influences immune, metabolic, and neurological systems. This innovative approach presents opportunities to collaborate with biotech firms and pharma companies seeking novel microbiome-based therapies for inflammatory diseases and cancer.

Focus on Inflammatory and Cancer Treatments The company's pipeline includes several candidates, such as EDP1815 and EDP2939, targeting psoriasis, atopic dermatitis, and cancer. Partnering with Evelo could expand therapeutic options for clients in dermatology and oncology sectors seeking advanced systemic therapies.

Recent Financial Challenges Following clinical trial setbacks and a significant staff reduction, Evelo is likely open to strategic partnerships, licensing deals, or investment opportunities to accelerate product development and regain market momentum.

Growth Through Strategic Collaborations Evelo's partnership with Jameel Investment Management Co. highlights a willingness to collaborate for commercializing inflammatory disease treatments. Similar partnerships could be advantageous for clients aiming to co-develop or distribute microbiome-based therapies.

Technology-Driven Innovation Utilizing advanced tech stacks like React, Squarespace, and Google Fonts API, Evelo demonstrates a modern, innovative digital presence. This positions the company as a forward-thinking partner for tech-enabled biotech solutions and digital health collaborations.

Evelo Biosciences Tech Stack

Evelo Biosciences uses 8 technology products and services including Akamai, Mailchimp, Twemoji, and more. Explore Evelo Biosciences's tech stack below.

  • Akamai
    Content Delivery Network
  • Mailchimp
    Email
  • Twemoji
    Font Scripts
  • Google Cloud
    Infrastructure As A Service
  • Modernizr
    Javascript Libraries
  • Adobe Tag Manager
    Tag Management
  • Box
    Team Collaboration
  • OpenResty
    Web Servers

Media & News

Evelo Biosciences's Email Address Formats

Evelo Biosciences uses at least 1 format(s):
Evelo Biosciences Email FormatsExamplePercentage
FLast@evelobio.comJDoe@evelobio.com
64%
First@evelobio.comJohn@evelobio.com
20%
Last@evelobio.comDoe@evelobio.com
15%
First.Last@evelobio.comJohn.Doe@evelobio.com
1%

Frequently Asked Questions

Where is Evelo Biosciences's headquarters located?

Minus sign iconPlus sign icon
Evelo Biosciences's main headquarters is located at Cambridge, Massachusetts 02139 United States. The company has employees across 4 continents, including North AmericaEuropeAsia.

What is Evelo Biosciences's phone number?

Minus sign iconPlus sign icon
You can contact Evelo Biosciences's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Evelo Biosciences's stock symbol?

Minus sign iconPlus sign icon
Evelo Biosciences is a publicly traded company; the company's stock symbol is EVLO.

What is Evelo Biosciences's official website and social media links?

Minus sign iconPlus sign icon
Evelo Biosciences's official website is evelobio.com and has social profiles on LinkedInCrunchbase.

What is Evelo Biosciences's SIC code NAICS code?

Minus sign iconPlus sign icon
Evelo Biosciences's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Evelo Biosciences have currently?

Minus sign iconPlus sign icon
As of June 2026, Evelo Biosciences has approximately 17 employees across 4 continents, including North AmericaEuropeAsia. Key team members include Chief Financial Officer: J. P.Chief Scientific Officer And President Research And Development: M. B.Head Of Translational Medicine: M. Y.. Explore Evelo Biosciences's employee directory with LeadIQ.

What industry does Evelo Biosciences belong to?

Minus sign iconPlus sign icon
Evelo Biosciences operates in the Biotechnology Research industry.

What technology does Evelo Biosciences use?

Minus sign iconPlus sign icon
Evelo Biosciences's tech stack includes AkamaiMailchimpTwemojiGoogle CloudModernizrAdobe Tag ManagerBoxOpenResty.

What is Evelo Biosciences's email format?

Minus sign iconPlus sign icon
Evelo Biosciences's email format typically follows the pattern of FLast@evelobio.com. Find more Evelo Biosciences email formats with LeadIQ.

How much funding has Evelo Biosciences raised to date?

Minus sign iconPlus sign icon
As of June 2026, Evelo Biosciences has raised $26M in funding. The last funding round occurred on Jul 10, 2023 for $26M.

When was Evelo Biosciences founded?

Minus sign iconPlus sign icon
Evelo Biosciences was founded in 2015.

Evelo Biosciences

Biotechnology ResearchMassachusetts, United States11-50 Employees

Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

Section iconCompany Overview

Headquarters
Cambridge, Massachusetts 02139 United States
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
EVLO
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
11-50

Section iconFunding & Financials

  • $26M

    Evelo Biosciences has raised a total of $26M of funding over 8 rounds. Their latest funding round was raised on Jul 10, 2023 in the amount of $26M.

  • $10M$25M

    Evelo Biosciences's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $26M

    Evelo Biosciences has raised a total of $26M of funding over 8 rounds. Their latest funding round was raised on Jul 10, 2023 in the amount of $26M.

  • $10M$25M

    Evelo Biosciences's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.